STOCK TITAN
  1. Home
  2. Sec-filings
  3. MD
  4. [Form 4] Pediatrix Medical Group, Inc. Insider Trading Activity

Pediatrix (MD) director Linynsky receives 7,196-share restricted stock award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Linynsky Laura A reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group director Laura A. Linynsky received a grant of 7,196 shares of restricted common stock as an annual equity award. The grant was made at no cash cost per share under the company’s Amended and Restated 2008 Incentive Compensation Plan. These restricted shares are scheduled to vest on May 7, 2027, meaning they become fully owned if service conditions are met. Following this award, Linynsky directly holds a total of 39,428 shares of Pediatrix Medical Group common stock.

Positive

  • None.

Negative

  • None.
Insider Linynsky Laura A
Role null
Type Security Shares Price Value
Grant/Award Common Stock 7,196 $0.00 --
Holdings After Transaction: Common Stock — 39,428 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Restricted shares granted 7,196 shares Annual equity award on May 7, 2026
Grant price per share $0.0000 per share Restricted stock award, non-cash compensation
Shares after transaction 39,428 shares Total common stock held directly after award
Vesting date May 7, 2027 Restricted shares vesting schedule
Restricted shares financial
"Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"
Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.
Amended and Restated 2008 Incentive Compensation Plan financial
"granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award"
annual equity award financial
"pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Linynsky Laura A
(Last)(First)(Middle)
1301 CONCORD TERRACE
(Street)
SUNRISE FLORIDA 33323
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/07/2026A(1)7,196A$039,428D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 7, 2027.
Mary Ann E. Moore, Attorney-in-Fact05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Pediatrix Medical Group (MD) report for Laura A. Linynsky?

Pediatrix Medical Group reported that director Laura A. Linynsky received a grant of 7,196 restricted shares of common stock. The award was made at no cash cost per share as part of her annual equity compensation under the company’s incentive plan.

When do Laura A. Linynsky’s new restricted Pediatrix (MD) shares vest?

The 7,196 restricted shares granted to Laura A. Linynsky are scheduled to vest on May 7, 2027. Vesting means the restrictions lapse at that date, assuming conditions are satisfied, and she then fully owns the shares without forfeiture risk.

How many Pediatrix (MD) shares does Laura A. Linynsky hold after this Form 4 transaction?

After the reported grant, Laura A. Linynsky directly holds 39,428 shares of Pediatrix Medical Group common stock. This figure reflects her updated ownership position immediately following the 7,196-share restricted stock award disclosed in the Form 4 filing.

What does the transaction code “A” mean in the Pediatrix (MD) Form 4 for Laura A. Linynsky?

The transaction code “A” on the Form 4 indicates a grant, award, or other acquisition of securities. In this case, it represents an equity compensation grant of restricted shares rather than an open-market purchase, so no price was paid per share.

Under which plan were the new Pediatrix (MD) restricted shares granted to Laura A. Linynsky?

The restricted shares were granted under Pediatrix Medical Group’s Amended and Restated 2008 Incentive Compensation Plan. This plan governs equity-based awards such as restricted stock, typically used to align director and executive compensation with long-term shareholder interests.

Is Laura A. Linynsky’s Pediatrix (MD) Form 4 transaction a market buy or a compensation grant?

The Form 4 shows a compensation grant, not a market purchase. Laura A. Linynsky received 7,196 restricted shares at a stated price of zero per share as an annual equity award rather than buying shares on the open market.